Measurement-Based Care: How We Track Whether Treatment Is Working

Measurement-based care is a simple idea with good evidence behind it: instead of relying only on “How have you been?”, the clinician asks you to complete the same short, validated questionnaires at regular points and uses the trend to guide decisions about continuing, adjusting or changing treatment. This page explains the model from the practice side: what it is, what the research shows, how scores feed into shared decisions, and where a cognitive assessment fits. For the patient how-to (scoring the PHQ-9 and GAD-7 yourself, keeping a side-effect log), see our guide to measuring medication response.

What measurement-based care means

A 2019 review in JAMA Psychiatry defines measurement-based care as the systematic evaluation of patient symptoms before or during an encounter to inform behavioral health treatment. The key words are systematic and inform: the same instrument, at planned intervals, actually used in the conversation. The same review notes that it is underused, typically by fewer than 20% of behavioral health practitioners.

In practice that usually means brief self-report scales: the PHQ-9 for depression, the GAD-7 for anxiety, and the ASRS for adult ADHD symptoms. Each takes a few minutes. Which questionnaires you will be asked to complete, and how often, is something to ask our team at your first visit.

What the research shows

The evidence is strongest in depression treated with medication.

• A randomized trial with blinded raters (Guo and colleagues, 2015) assigned 120 outpatients with moderate to severe depression to measurement-based care or usual care for 24 weeks. With measurement guiding decisions, 86.9% responded versus 62.7%, and 73.8% reached remission versus 28.8%. Time to response was 5.6 weeks versus 11.6. The measured group had more treatment adjustments; dropout and side effects did not differ.
• A 2017 review of 51 articles (Fortney and colleagues) found that virtually all randomized trials feeding patient-reported symptoms back to the clinician frequently and in time for the visit improved outcomes. What did not work: one-time screening, infrequent measurement, and feedback delivered outside the visit.
• A 2021 meta-analysis of seven trials with 2,019 participants found higher remission rates, lower end-of-treatment severity and better medication adherence with measurement-based care, but no significant difference in response rates. The authors flagged few trials and a high risk of bias.
• STAR*D, a large real-world depression study of 2,876 outpatients, built measurement into routine visits: symptoms and side effects at every visit, with a manual for when to change course.

So the honest summary: frequent measurement, used in the visit, tends to help people get better faster and more completely, with the clearest data in depression. It is not magic, and the trials vary in quality.

How measurement fits into your visits

In a measurement-based approach, the questionnaire is the start of the conversation, not a form for the chart. A typical cycle looks like this:

1. Baseline at the first evaluation. Your starting scores, alongside your history, become the reference point.
2. Repeat before follow-ups. The same questionnaire before each visit, so the clinician sees the line, not just a dot.
3. Review together. Is the trend moving? Which items are improving and which are stuck? Does the number match how your life is going?
4. Decide together. Continue, give it more time, adjust, add or switch, based on the trend plus side effects, your goals and your preferences.

Willow & Stone’s follow-up visits run 25–50 minutes ($150), which leaves room to go through scores rather than glance at them. The practice’s approach to medication management describes those visits more broadly. If you like to track at home between visits, the guide to measuring your own medication response shows how.

What change counts as meaningful

Clinicians usually think in terms of a target rather than any change at all. The AIMS Center at the University of Washington, a center for collaborative care, advises aiming for at least a 50% reduction in symptoms and changing the treatment plan if that hasn’t happened, within 10–12 weeks in collaborative care.

Several things make a single number less certain than it looks:

• Ordinary fluctuation. A rough two weeks after a family crisis can raise a score without meaning treatment failed.
• Items move differently. Sleep and energy often improve before mood or interest; a total can hide that.
• Function matters as much as symptoms. A lower score with work and relationships still stuck is a partial answer.

The definitions of response, remission and partial response, with worked examples, are on the medication response page; we won’t repeat them here.

How the trend shapes treatment decisions

Scores are one input among several, but they change the timing and direction of decisions. When a trend is clearly improving, the usual choice is to stay the course. When improvement stalls well short of the target, measurement makes the plateau visible earlier, and the options get discussed: more time, an adjustment, adding therapy or another treatment, or a switch. Our pages on how an antidepressant switch is done and why an antidepressant can stop working cover those paths.

For ADHD, rating scales track day-to-day symptoms and functioning, and a rising score after a period of stability is a reason to look at sleep, stress, hormones and other factors before assuming the medication has failed; see why ADHD medication can seem to stop working.

Decisions about medication are always made with your prescriber. Please don’t change a dose or stop a medication on your own because of a score.

Where a cognitive baseline fits, and where it doesn’t

Willow & Stone offers Creyos, a computerized assessment of memory, attention, reasoning and verbal ability compared with people your age; the Creyos guide explains it. In a measurement-based model it is optional. When thinking problems are part of your picture, your clinician may suggest it as a baseline and may repeat it later to compare.

That comparison has real limits. Scores are normed to people’s first attempt, so a second attempt tends to be a little higher simply from practice. Test-retest reliability in Creyos’s own data averages about 0.69 and is lower for some tasks, and its Meaningful Change Indicator uses a lenient statistical threshold. Sleep and mood on the day move results too. There is no published evidence that Creyos scores track medication response, so they should not be used that way. Retesting and practice effects goes into detail.

Whether a Creyos assessment is part of your care, what it costs, and when a repeat would happen are confirmed when you book. Creyos is registered and listed with the FDA as a Class II, 510(k)-exempt computerized cognitive assessment aid; it is not FDA-cleared or approved and does not diagnose any condition.

When a score signals a safety concern

Some questionnaires ask directly about thoughts of death or self-harm, such as the ninth item of the PHQ-9. That question is there because it matters, and an honest answer helps your clinician help you. It will not get you in trouble.

Between visits, if scores jump sharply or you notice new or stronger thoughts of self-harm, contact the practice rather than waiting for the next questionnaire.

Getting started

Measurement starts at the first visit: the 90-minute evaluation ($300) sets your baseline, and follow-ups track it. Insurance is accepted for Texas patients only, depending on the plan; elsewhere care is direct-pay with a superbill. See pricing and book through the consultation page. Bring any scores you’ve already tracked; they are useful history.

Common Questions

Sources & Further Reading

• Lewis CC et al. Implementing Measurement-Based Care in Behavioral Health: A Review. JAMA Psychiatry 2019 (PMC)
• Fortney JC et al. A Tipping Point for Measurement-Based Care. Psychiatr Serv 2017 (PubMed 27582237)
• Guo T et al. Measurement-Based Care Versus Standard Care for Major Depression: A Randomized Controlled Trial With Blind Raters. Am J Psychiatry 2015 (PubMed 26315978)
• Zhu M et al. The Efficacy of Measurement-Based Care for Depressive Disorders: Systematic Review and Meta-Analysis. J Clin Psychiatry 2021
• Trivedi MH et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D. Am J Psychiatry 2006 (PubMed 16390886)
• AIMS Center, University of Washington — Measurement-Based Treatment to Target
• Creyos — Science Overview (PDF), test-retest reliability table
• Creyos — Report Interpretation Guide (PDF)

This article is general education, not a diagnosis or advice for your situation. Creyos results support, and never replace, a clinical evaluation; only a clinician who has evaluated you can diagnose a condition or recommend treatment. Do not start, stop, or change a medication without talking to the clinician who prescribes it.